The global endotracheal tube market is projected to expand at a CAGR of 6.5% during the forecast period of 2024 to 2032. Increasing incidences of chronic diseases such as cardiovascular disease, cancer, and other respiratory diseases have led to an increase in the number of surgical procedures requiring endotracheal tubes. According to the 2019 World Health Organization report, respiratory diseases are the leading cause of death worldwide, accounting for approximately 4.0 million deaths annually. Consequently, the market is anticipated to exhibit lucrative growth over the coming years.
Increased Number of Surgical Procedures to Boost the Market Growth
The demand for endotracheal tubes has been fuelled by an increase in the number of surgeries. According to the report Global Surgery and Anaesthesia Statistics, approximately 313,0 million surgical procedures are performed annually. In addition to reducing the risk of infection associated with tubes, technological advances in endotracheal intubation have enhanced product safety. Patients who have been on an endotracheal tube or mechanical ventilator for more than 48 hours are the most likely to develop Ventilator-Associated Pneumonia (VAP), a condition that has been on the rise. Thus, numerous market participants are developing products with antimicrobial and anticoagulant coatings that can reduce VAP. For instance, it has been reported that Medtronic Shiley Evac endotracheal tubes reduce VAP by 50.0%. Consequently, as the incidence of VAP rises, so does the demand for coated endotracheal tubes, fueling the market's expansion. Consequently, technological advancements in endotracheal tubes and an aging population that is increasingly susceptible to numerous chronic diseases will increase the market's growth opportunities during the forecast period.
Pandemic Impact Boosted the Market Growth and Innovations
As breathing difficulty is a clear indication of infection, the emergence of COVID-19 has greatly increased the demand for endotracheal tubes, which has fueled the market expansion. In cases of respiratory failure in COVID patients, the American Association for Bronchology and Interventional Pulmonology suggests Open Surgical Tracheostomy (OST) or percutaneous dilatational tracheostomy. This pandemic made emergency product approvals possible. N8, a U.S.-based biotechnology company, obtained emergency use authorization from Health Canada for its CeraSheild Endotracheal Tubes in COVID-19 patients receiving mechanical ventilation. The anti-fouling coating on the company's patented product is designed to prevent deadly bacterial infections. Endotracheal intubation and ventilation support a COVID-19 patient's breathing so that the patient can survive while the immune system battles the virus. This increases the likelihood of successfully combating the virus. Such scenarios are anticipated to stimulate market expansion
Increasing Product Approvals and Launches Are Anticipated to Drive Market Expansion During the Forecast Period.
Increased launches and approvals of advanced and efficient endotracheal tubes by key players are anticipated to propel the endotracheal tube market over the coming years. In November 2016, Bactiguard introduced the BIP Endotracheal Tube Evac to prevent ventilator-associated pneumonia in patients (VAP). To prevent ventilator-associated pneumonia (VAP) infections, the innovative BIP Endotracheal Tube Evac has subglottic secretion drainage and a Bactiguard coating.
Increasing Technological Advances in Endotracheal Tubes Are Anticipated to Propel Market Growth During the Forecast Period
In order to prevent hospital-acquired infections, manufacturers are emphasizing the creation of innovative endotracheal tubes. For instance, in February, N8 Medical, LLC submitted to the Food and Drug Administration (FDA) the Investigational Device Exemption (IDE) for the first-in-human clinical study of its CeraShield Endotracheal Tube (ETT). The purpose of the clinical trial is to assess the safety and effectiveness of the CeraShield Endotracheal Tube (ETT).
Nonetheless, the increasing prevalence of hospital-acquired infections, such as ventilator-associated pneumonia, is anticipated to restrain the growth of the endotracheal tube market during the forecast period. According to the National Center for Biotechnology Information, the incidence of ventilator-associated pneumonia (VAP) in the United States ranged from 2 to 16 episodes per 1,000 ventilator days in November 2017.
Risk of Nosocomial Infections to Inhibit the Market Growth
Hospitals that have acquired infections such as pneumonia associated with mechanical ventilation are driving the growth of the intubation tube market. In intensive care units, patients are at the highest risk of death due to procedure complications or other causes, one of which is a critical illness caused by secondary processes, such as nosocomial infection.
Pneumonia, which affects 27% of critically ill patients, is the second most common nosocomial infection, after urinary tract infections. Nearly 86% of nosocomial pneumonia is caused by pneumonia associated with mechanical ventilation.
Mortality associated with ventilator-associated pneumonia has been estimated to range between 0% and 50%. When it comes to assessing attributable mortality, different studies have yielded divergent results due to the diversity of the populations examined.
Regular Endotracheal Tubes Dominated the Market by Type
In 2023, the segment of regular endotracheal tubes dominated the market and held the largest revenue share of 32.5% due to the increasing number of surgical procedures as a result of the rising prevalence of respiratory diseases. Also, as the incidence of VAP rises, the demand for endotracheal tubes is anticipated to increase in the future. As a result, the segment is anticipated to exhibit lucrative growth over the forecast period. The market has been divided into regular endotracheal tubes, reinforced endotracheal tubes, performed endotracheal tubes, and double-lumen endotracheal tubes based on the type of product.
However, the reinforced endotracheal tube segment is expected to grow at a faster rate over the forecast period due to its increasing use during surgery and recent technological advancements in endotracheal tubes. In addition, the increasing incidence of road accidents and trauma injuries will contribute to the segment's growth over the forecast period.
Orotracheal Segment Dominated the Market by Route Type
In 2023, the orotracheal segment held the largest revenue share of 65% of the market. The market has been classified as orotracheal and nasotracheal based on route type. Orotracheal has the largest market share due to its broad applicability, increased utilization, and comfort. Orotracheal intubation is utilized to control the airway of any surgical patient. It is also used for patients with severe injuries or multisystem diseases who are critically ill.
Orotracheal incubation is commonly used in emergency situations such as respiratory or cardiac arrest, inadequate oxygenation or ventilation, failure to protect the airway from aspiration, and existing or anticipated airway obstruction. Due to this, the demand for orotracheal tubes has increased over the past few years, and the segment is expected to grow at a healthy rate over the forecast period. Additionally, the aforementioned factors will increase demand for orotracheal intubation over the forecast period. Due to the rising prevalence of respiratory disease, it is anticipated that the nasotracheal segment will experience the highest CAGR of 5.6% during the forecast period.
The Emergency Treatment Market Dominated the Application Segment
In 2023, the emergency treatment segment held the largest revenue share of 55% of the market. The market is further segmented by application into emergency treatment, therapy, and others. The largest share of this segment can be attributed to the rising incidence of emergency conditions such as cardiac arrest and respiratory, airway obstruction and inadequate ventilation, rising cases of road accidents, and growing disposable income in developing nations. Nonetheless, the therapy segment is anticipated to experience greater growth during the forecast period. During the forecast period, the segment's growth will be driven primarily by the increasing volume of surgical procedures, the prevalence of chronic respiratory diseases, and the aging population.
Hospital Segment Dominated the End User Market
In 2023, the hospital's segment held the largest revenue share at over 35% due to the global trend toward hospitalization. The market has been segmented by end-use into hospitals, ambulatory surgical centers, clinics, and others. In addition, high awareness among hospital physicians and nursing staff contributes to the segment's increasing market share. The clinics market segment is anticipated to experience the greatest growth during the forecast period. The increasing prevalence of chronic respiratory diseases, rising awareness of the benefits of clinics, and equitable reimbursement policies will drive the expansion of this market segment. However, ambulatory surgical centers are also anticipated to experience significant growth over the forecast period due to the expansion of centers in North America and Asia-Pacific.
North America to Dominate the Revenue Share and APAC to Emerge as Growth Leader
Due to its advanced healthcare system and rising prevalence of chronic diseases, North America dominated the endotracheal tubes market in 2023, accounting for more than 35% of the global revenue. In addition, the presence of significant market participants in the region contributed to market expansion. Teleflex Incorporated, Medline Industries, and Medtronic are three of the region's most prominent companies.
In 2023, the United States contributed over 30% of the global Intubation Tube Market revenue. The increase in tracheal diseases, such as tracheal stenosis, bronchial tumors, and tracheobronchomalacia, has increased the country's demand for intubation tubes. The National Cancer Institute estimates that there will be 236 740 new cases of lung and bronchial cancer in the United States in 2023, which represents 12.3% of all new cancer cases. This will bring the death toll for this disorder to 130,180, or 21.4% of all cancer-related deaths in the country.
Asia-Pacific is anticipated to experience the market's fastest growth over the forecast period. The increasing geriatric population with respiratory disease, rising prevalence of ventilator-associated pneumonia, and rising number of surgeries due to chronic cardiovascular disease are expected to increase regional demand for endotracheal tubes.
Technology Innovation to Remain as the Key to Enhance Market Shares
The rapid adoption of advanced healthcare technology for enhanced healthcare is a crucial factor influencing the market's competitiveness. In addition to new product launches, major players frequently engage in mergers and acquisitions in order to retain market share and diversify their product portfolios. Medtronic Plc, Teleflex Inc., ConvaTec Inc., Smiths Medical, Neurovision Medical Products, Intersurgical Inc., Royax, Novo Klinik-Service GmbH, Avanos Medical, Inc., Bactiguard, N8 Medical LLC and Other Notable Players are some of the key players in the endotracheal tube market.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Endotracheal Tubes market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2022-2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Year | 2022 |
| Unit | USD Million |
| Segmentation | |
Product
| |
Route Type
| |
Application
| |
End-use
| |
|
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report
